Pfizer Saudi Limited signed an exclusive commercial agreement with Tabuk Pharmaceuticals. The deal will permit Pfizer to advertise and promote branded and high-value generic drugs, such as medicines that provide treatment for kidney dialysis, kidney transplant, urology, and the central nervous system. This agreement is part of a larger Vision 2030 effort to strengthen local manufacturing capabilities. Pfizer started production at a $50 million plant in Saudi Arabia in January.
Pfizer Signs Commercial Agreement
You also might be interested in
The Public Investment Fund (PIF) invested $506 million (SR1.9 billion)[...]
The American IT giant Oracle, which specializes in cloud computing[...]
The Business extension of the G20 Presidency, B20 Saudi Arabia, announced[...]